Anc 80L65-arylsulfatase A - AFFINIA THERAPEUTICS
Alternative Names: Anc80L65-arylsulfatase A - AFFINIA THERAPEUTICSLatest Information Update: 29 Sep 2021
Price :
$50 *
At a glance
- Originator AFFINIA THERAPEUTICS
- Class Gene therapies
- Mechanism of Action Arylsulfatase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Metachromatic leukodystrophy
Most Recent Events
- 13 Sep 2021 Anc 80L65-arylsulfatase A - AFFINIA THERAPEUTICS is available for licensing as of 13 Sep 2021. https://www.affiniatx.com/our-science/our-platform/
- 08 Sep 2021 Preclinical trials in Metachromatic leukodystrophy in USA (Intrathecal)
- 08 Sep 2021 AFFINIA THERAPEUTICS plans a clinical trial for Metachromatic leukodystrophy